Explain the Role of Tezspire in Severe Asthma
December 2022
Tezspire (tezepelumab) will be the newest biologic for severe asthma in patients 12 years and up.
It’s the latest injectable monoclonal antibody, or “MAb,” for asthma...after Xolair (omalizumab), Dupixent (dupilumab), etc.
Tezspire is the first MAb to target a protein called “thymic stromal lymphopoietin” (TSLP). Many patients with asthma have higher levels of TSLP...so the theory is that blocking it may improve asthma symptoms.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive